Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Renal, and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for WNK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WNK1 Active Kinase Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/Insect expressed for native phosphorylation. |
View WNK1 Products |
| Gene Delivery | WNK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based volume regulation assays. |
View WNK1 Products |
| Benchmark Ab | Anti-WNK1 Recombinant Antibody Recombinant positive control for western blot and immunofluorescence. |
View WNK1 Products |
| Validator | WNK1 siRNA Set For target knockdown verification and specificity controls in cell assays. |
View WNK1 Products |
| Related Target A | STK39 (SPAK) Downstream substrate of WNK1; critical node in the WNK-SPAK-NCC signaling cascade. |
View STK39 Products |
| Related Target B | OXSR1 (OSR1) Closely related SPAK homolog; co-mediates WNK1-dependent ion co-transporter regulation. |
View OXSR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter screening (WNK2/3/4) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis to prevent off-target profiling errors. |
| Kinase assay signal-to-noise ratio | Sf9 insect cell-expressed kinase domains with high purity (>95%) and controlled aggregation profiles. |
| Lack of Controls | Clinical Benchmark Antibodies and Kinase-Dead mutant proteins included in the catalog. |
| False Positives in phenotypic screens | Sequence-verified siRNA pool included for target validation. |
Live WNK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for WNK1 therapeutics is intensifying, with major players shifting focus from traditional systemic vasodilators to selective small molecule kinase inhibitors targeting the WNK-SPAK-NCC pathway. As first-generation therapies for hypertension and pseudohypoaldosteronism type II (PHAII) reach preclinical and early clinical milestones, the next wave of R&D is targeting oncology indications, specifically glioblastoma and breast cancer cell migration, where WNK1 plays a non-canonical role in volume regulation and invasiveness.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Sanofi, Academic Consortia | Hypertension, Ischemic Stroke | Selectivity Assay (Need Mutant vs WT Proteins and WNK homologs) |
| Small Molecule (Kinase Inhibitor) | Biopharma Startups | Glioblastoma, Cancer Metastasis | In vitro Kinase Profiling (Need high-purity active kinase domains) |
| siRNA / RNAi | RNA Therapeutics Specialists | Renal Tubular Acidosis, PHAII | Target Knockdown Validation (Need validated siRNA and Lentivirus controls) |